Genprex receives Nasdaq delisting notice due to sub-$1 bid price; ineligible for compliance period

Genprex, Inc.

• Nasdaq staff determined on June 10, 2026 to delist GNPX due to bid price below $1.00 for 30 consecutive days.
• Company is ineligible for a 180-day compliance period because it effected a reverse stock split on October 21, 2025.
• Genprex intends to timely request a hearing before a Nasdaq Hearings Panel, which will stay delisting pending outcome.
• Options to regain compliance include a potential further reverse stock split; no assurance of success.
• Delisting could materially reduce stock liquidity, market price, and ability to raise capital.